Blue Jet Healthcare Ltd Falls to 52-Week Low of Rs.472.2

Stock Price Movement and Market Context

On 19 Jan 2026, Blue Jet Healthcare Ltd opened with a gap down of -2.23%, touching an intraday low of Rs.472.2, which represents the lowest price point for the stock in the last 52 weeks. Despite this, the stock managed a modest recovery by the close, outperforming its Pharmaceuticals & Biotechnology sector by 1.23% on the day. However, it remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a sustained downward trend.

In comparison, the broader market benchmark, the Sensex, experienced a negative session, falling by 480.02 points (-0.67%) to close at 83,014.47. The Sensex is currently trading 3.79% below its 52-week high of 86,159.02 and has been on a three-week consecutive decline, losing 3.2% over that period. While the Sensex trades below its 50-day moving average, the 50DMA remains above the 200DMA, signalling mixed medium-term market momentum.

Financial Performance and Valuation Metrics

Blue Jet Healthcare Ltd’s financial results have contributed to the stock’s subdued performance. The company reported flat results in the quarter ending September 2025, with a notable decline in profit after tax (PAT). The quarterly PAT stood at Rs.52.14 crores, down by 41.8% compared to the average of the previous four quarters. Operating cash flow for the year was also at a low of Rs.45.76 crores, reflecting constrained liquidity generation.

Additionally, the company’s debtors turnover ratio for the half-year was recorded at 0.38 times, the lowest in recent periods, suggesting slower collection efficiency. Despite these near-term pressures, Blue Jet Healthcare maintains a strong long-term fundamental profile, with an average return on equity (ROE) of 23.5% and a current ROE of 28.1%. Net sales have grown at an annual rate of 25.62%, while operating profit has expanded by 38.55% annually, underscoring healthy underlying business growth.

Valuation Considerations

The stock currently trades at a price-to-book value of 6.7, indicating a relatively expensive valuation compared to its book value. However, it is priced at a discount relative to its peers’ average historical valuations. The company’s price-to-earnings-to-growth (PEG) ratio stands at 0.2, reflecting the relationship between its valuation and earnings growth potential. Despite the recent price decline, Blue Jet Healthcare’s market capitalisation grade is rated 3, and its overall Mojo Score is 46.0, with a Mojo Grade downgraded from Hold to Sell as of 6 Jan 2026.

Performance Relative to Benchmarks

Over the past year, Blue Jet Healthcare Ltd’s stock has declined by 18.86%, underperforming the Sensex, which gained 8.40% during the same period. The stock’s 52-week high was Rs.1,028.2, highlighting the extent of the recent price correction. Furthermore, the stock has underperformed the BSE500 index over the last three years, one year, and three months, indicating challenges in maintaining consistent market outperformance.

Despite the price decline, the company’s profits have risen by 101.3% over the past year, a notable contrast to the stock’s negative return. This divergence suggests that market sentiment and valuation adjustments have played a significant role in the stock’s price movement.

Balance Sheet and Shareholding Structure

Blue Jet Healthcare Ltd benefits from a low average debt-to-equity ratio of zero, reflecting a conservative capital structure with minimal leverage. The majority shareholding is held by promoters, providing stability in ownership. This financial prudence supports the company’s capacity to sustain growth initiatives and manage risks effectively.

Summary of Key Metrics

To summarise, Blue Jet Healthcare Ltd’s stock has reached a 52-week low of Rs.472.2 amid a backdrop of subdued quarterly earnings, reduced profit after tax, and lower operating cash flow. The stock’s valuation remains elevated on a price-to-book basis but is discounted relative to peers historically. The company’s strong long-term fundamentals, including robust ROE and healthy sales and profit growth, contrast with recent price weakness and underperformance against market indices.

Market participants will note the stock’s current Mojo Grade of Sell, reflecting a cautious stance based on recent financial and price trends. The stock’s trading below all major moving averages further underscores the prevailing downward momentum in the near term.

Unlock special upgrade rates for a limited period. Start Saving Now →